• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    5/15/23 7:30:14 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email

    Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience

    Vikram Jog to become Special Advisor for transition period

    SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to the CEO to ensure an effective transition.

    "We are excited to welcome Jeff to the Standard BioTools executive leadership team. Jeff has a proven track record of driving performance for high-growth public companies and his extensive operating experience and financial stewardship will be critical as Standard BioTools enters its next phase of growth," said Egholm. "I also want to extend my gratitude to Vikram, who has been a steady hand and clear thinker as we navigated the strategic transformation throughout our first year as Standard Biotools."

    Mr. Black was most recently Chief Financial Officer at Apollo Endosurgery, Inc. until Apollo's acquisition by Boston Scientific in April 2023. Mr. Black has also served in senior finance leadership roles for seven publicly traded companies, including as Executive Vice President and Chief Financial Officer of Alphatec Holdings, Inc., a medical technology company. Previously, Mr. Black was Chief Financial Officer of Applied Proteomics, Inc., a proteomics-based diagnostics company, and as Chief Financial Officer of AltheaDx, Inc., a pharmacogenetics diagnostics company. Mr. Black began his career in the audit practice at EY. He is a member of the Board of Directors of Cellana, Inc., an algae bioproducts company, and received his B.S. in Business from the University of Arizona.

    "I am thrilled to join this high-caliber leadership team and dynamic organization," said Black. "This team is building an exceptional company that will be the next great provider of solutions to researchers around the world. There is a tremendous opportunity ahead to greatly impact patient lives and unlock shareholder value. I am delighted to be a part of Standard BioTools as it continues to execute on its mission."

    As a material inducement for Mr. Black to commence employment with Standard BioTools, on May 15, 2023, Mr. Black will receive an award of non-statutory stock options to purchase 400,000 shares of the Company's common stock ("Option Award"). The Option Award will have a 10-year term and an exercise price per share equal to the closing price of the company's common stock as quoted on the Nasdaq Global Select Market on May 15, 2023. Subject to his continued employment with the company through the applicable vesting dates, 25% of the shares subject to the Option Award will vest on the first anniversary of the vesting commencement date, and the remaining 75% of the shares subject to the Option Award will vest in roughly equal monthly installments thereafter. In addition, as a material inducement for Mr. Black to commence employment with the company, on May 15, 2023 he will receive an award of restricted stock units valued at $400,000 ("RSU Award") based on the closing price of the company's common stock on May 15, 2023. Subject to his continued employment with the company, 25% of the shares underlying the RSU Award will vest on the first anniversary of the vesting commencement date and the remaining 75% of the shares underlying the RSU Award will vest in roughly equal installments every three months thereafter until fully vested in May 2027. The Option Award and RSU Award will be subject to the terms of the company's 2022 Inducement Equity Incentive Plan and the applicable award agreements thereunder. In accordance with Nasdaq Listing Rule 5635(c)(4), a majority of the independent directors serving on the company's Board of Directors approved Mr. Black's inducement awards.

    About Standard BioTools Inc. 

    Standard BioTools Inc. (NASDAQ:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, "Unleashing tools to accelerate breakthroughs in human health," Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

    Available Information 

    Standard BioTools uses its website (standardbio.com), investor site (investors.standardbio.com), corporate Twitter account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools' website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts. 

    Investor Contacts 

    Scott R. Greenstone, CFA

    [email protected] 

    Peter DeNardo 

    415 389 6400 

    [email protected]



    Primary Logo

    Get the next $LAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Troy was granted 94,592 shares, increasing direct ownership by 58% to 256,412 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 7:00:22 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Eloi Fenel M was granted 94,592 shares, increasing direct ownership by 67% to 236,183 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:52 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Carey Thomas D. was granted 94,592 shares, increasing direct ownership by 95% to 194,058 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:06 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      3/4/25 8:19:51 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/29/24 8:30:41 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $1,546,237 worth of shares (750,000 units at $2.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/26/24 8:10:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

      SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

      7/21/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

      Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milesto

      6/23/25 7:13:00 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

      Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business   Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina"), including Soma

      6/23/25 7:05:18 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    SEC Filings

    See more
    • Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/23/25 9:11:17 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/20/25 4:16:03 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Standard BioTools Inc.

      SD - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/2/25 4:06:54 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Standard BioTools downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

      2/27/25 6:22:46 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • TD Cowen initiated coverage on Standard BioTools with a new price target

      TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

      4/16/24 8:09:43 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies initiated coverage on Standard BioTools with a new price target

      Jefferies initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.25

      4/4/24 7:41:52 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Standard BioTools Appoints Alex Kim as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

      11/7/24 8:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

      5/15/23 7:30:14 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Financials

    Live finance-specific insights

    See more
    • Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

      SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

      7/21/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Reports First Quarter 2025 Financial Results

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

      5/6/25 4:01:00 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor R

      4/22/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/14/24 3:32:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/12/24 6:01:47 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/4/24 1:59:57 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials